Company intelligence / Profile preview
US Specialty Formulations
Bethlehem, Pennsylvania, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's QYNDR oral COVID-19 vaccine completed a successful Phase I clinical trial in 2023, demonstrating safety and preliminary efficacy; company seeking partnerships for Phase II/III trials
- Therapeutic areas
- Infectious DiseasesOther
- Modalities
- Small moleculeVaccineBiologicBotanical pharmaceutical-grade extractSpecialty formulationOral mucosal vaccineSterile injectableTopical pharmaceutical
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
VaxForm (vaccine development partner)
Beyond the preview
Go deeper on US Specialty Formulations.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on US Specialty Formulations.